ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 190 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q3 2023. The put-call ratio across all filers is 0.86 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $444,001 | +16.1% | 81,468 | +43.0% | 0.00% | – |
| Q2 2023 | $382,329 | -16.3% | 56,979 | +10.2% | 0.00% | – |
| Q1 2023 | $456,732 | +24.0% | 51,725 | +7.3% | 0.00% | – |
| Q4 2022 | $368,439 | +18.1% | 48,225 | +10.0% | 0.00% | – |
| Q3 2022 | $312,000 | -12.6% | 43,835 | -0.7% | 0.00% | – |
| Q2 2022 | $357,000 | -66.7% | 44,127 | -42.8% | 0.00% | -100.0% |
| Q1 2022 | $1,071,000 | -8.5% | 77,135 | +85.1% | 0.00% | 0.0% |
| Q4 2021 | $1,170,000 | -11.2% | 41,681 | +7.6% | 0.00% | 0.0% |
| Q3 2021 | $1,317,000 | -13.0% | 38,741 | +4.6% | 0.00% | -50.0% |
| Q2 2021 | $1,513,000 | +84.1% | 37,035 | +81.4% | 0.00% | +100.0% |
| Q1 2021 | $822,000 | +195.7% | 20,419 | +334.3% | 0.00% | – |
| Q4 2020 | $278,000 | -70.3% | 4,702 | -75.7% | 0.00% | -100.0% |
| Q2 2020 | $936,000 | +17.6% | 19,352 | -27.3% | 0.00% | +100.0% |
| Q4 2019 | $796,000 | – | 26,603 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,377,665 | $12,958,274 | 12.23% |
| Eagle Health Investments LP | 1,214,860 | $6,620,987 | 1.46% |
| Matrix Capital Management Company, LP | 11,572,590 | $63,070,616 | 0.76% |
| Aristotle Atlantic Partners, LLC | 3,058,206 | $16,667,223 | 0.67% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $163,465,709 | 0.66% |
| Pier Capital, LLC | 719,067 | $3,918,915 | 0.63% |
| DDD Partners, LLC | 783,697 | $3,385,571 | 0.49% |
| ARK Investment Management | 11,509,308 | $62,725,728 | 0.48% |
| Nikko Asset Management Americas, Inc. | 6,570,939 | $35,680,199 | 0.43% |
| Triatomic Management LP | 102,889 | $560,745 | 0.39% |